pancreatic cancer

Radioactive drug for digestive cancer snags FDA approvalFDA approved a new drug to treat a type of cancer that affects the pancreas or gastrointestinal tract.
Genetic testing for melanoma riskPatients who carry a high-penetrance melanoma predisposition gene can often benefit from screening for other cancers. Patients who receive a positive genetic test result are more likely to embrace prevention and detection measures. A new “Rules of Three” proposes a point-based guideline to help determine who should be referred for genetic counseling and testing.
FDA approves new treatment for pancreatic cancerThe FDA approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.
FDA drug approvals-May 2015FDA actions in brief, complete response, breakthrough therapy designation, fast-track designations, orphan drug designations
Pancreatic cancer: Targeted treatments hold promiseCenter for Drug Evaluation and Research (CDER) Trade Press Scientists are working to develop breakthrough therapies for pancreatic cancer, one of the deadliest cancers affecting men and women.
FDA drug approvals-February 2015FDA actions in brief, priority review, breakthrough designations, orphan drug designations
FDA drug approvals-January 2015FDA actions in brief, recommendations for approval, fast-track designations.
FDA drug approvals December 2014
FDA actions in briefRecently approved drugs
FDA approves late-stage pancreatic cancer injectableFDA expanded the approved uses of paclitaxel protein-bound particles for injectable suspension, albumin-bound (Abraxane, Celgene) to treat patients with metastatic pancreatic cancer.